Cardiac, renal, and neurological benefits of preoperative levosimendan administration in patients with right ventricular dysfunction and pulmonary hypertension undergoing cardiac surgery: evaluation with two biomarkers neutrophil gelatinase-associated lipocalin and neuronal enolase
- PMID: 27143905
- PMCID: PMC4844253
- DOI: 10.2147/TCRM.S102772
Cardiac, renal, and neurological benefits of preoperative levosimendan administration in patients with right ventricular dysfunction and pulmonary hypertension undergoing cardiac surgery: evaluation with two biomarkers neutrophil gelatinase-associated lipocalin and neuronal enolase
Abstract
Purpose: To evaluate if the preoperative administration of levosimendan in patients with right ventricular (RV) dysfunction, pulmonary hypertension, and high perioperative risk would improve cardiac function and would also have a protective effect on renal and neurological functions, assessed using two biomarkers neutrophil gelatinase-associated lipocalin (N-GAL) and neuronal enolase.
Methods: This is an observational study. Twenty-seven high-risk cardiac patients with RV dysfunction and pulmonary hypertension, scheduled for cardiac valve surgery, were prospectively followed after preoperative administration of levosimendan. Levosimendan was administered preoperatively on the day before surgery. All patients were considered high risk of cardiac and perioperative renal complications. Cardiac function was assessed by echocardiography, renal function by urinary N-GAL levels, and the acute kidney injury scale. Neuronal damage was assessed by neuron-specific enolase levels.
Results: After surgery, no significant variations were found in mean and SE levels of N-GAL (14.31 [28.34] ng/mL vs 13.41 [38.24] ng/mL), neuron-specific enolase (5.40 [0.41] ng/mL vs 4.32 [0.61] ng/mL), or mean ± SD creatinine (1.06±0.24 mg/dL vs 1.25±0.37 mg/dL at 48 hours). RV dilatation decreased from 4.23±0.7 mm to 3.45±0.6 mm and pulmonary artery pressure from 58±18 mmHg to 42±19 mmHg at 48 hours.
Conclusion: Preoperative administration of levosimendan has shown a protective role against cardiac, renal, and neurological damage in patients with a high risk of multiple organ dysfunctions undergoing cardiac surgery.
Keywords: acute renal failure; brain; kidney; levosimendan; preoperative.
Figures


Similar articles
-
Preoperative urinary neutrophil gelatinase-associated lipocalin and outcome in high-risk heart failure patients undergoing cardiac surgery.J Cardiothorac Vasc Anesth. 2014 Apr;28(2):323-7. doi: 10.1053/j.jvca.2013.07.007. Epub 2013 Dec 2. J Cardiothorac Vasc Anesth. 2014. PMID: 24295718
-
The effect of levosimendan on the right ventricular function in patients with right ventricular dysfunction undergoing mitral valve surgery.Ann Card Anaesth. 2023 Jan-Mar;26(1):50-56. doi: 10.4103/aca.aca_179_21. Ann Card Anaesth. 2023. PMID: 36722588 Free PMC article. Clinical Trial.
-
Associations of Perioperative Renal Oximetry Via Near-Infrared Spectroscopy, Urinary Biomarkers, and Postoperative Acute Kidney Injury in Infants After Congenital Heart Surgery: Should Creatinine Continue to Be the Gold Standard?Pediatr Crit Care Med. 2019 Jan;20(1):27-37. doi: 10.1097/PCC.0000000000001767. Pediatr Crit Care Med. 2019. PMID: 30395106 Free PMC article.
-
Effect of levosimendan on prognosis in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials.Crit Care. 2017 Oct 17;21(1):253. doi: 10.1186/s13054-017-1848-1. Crit Care. 2017. PMID: 29041948 Free PMC article. Review.
-
Perioperative Use of Levosimendan Improves Clinical Outcomes in Patients After Cardiac Surgery: A Systematic Review and Meta-Analysis.J Cardiovasc Pharmacol. 2018 Jul;72(1):11-18. doi: 10.1097/FJC.0000000000000584. J Cardiovasc Pharmacol. 2018. PMID: 29672418
Cited by
-
Comparison of the Use of Desflurane vs. Propofol in Aortic Valve Replacement Surgery: Differences in Nephroprotection: An Explorative and Hypothesis-Generating Study.Life (Basel). 2022 Jul 31;12(8):1172. doi: 10.3390/life12081172. Life (Basel). 2022. PMID: 36013350 Free PMC article.
-
Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice.J Cardiovasc Pharmacol. 2018 Jan;71(1):1-9. doi: 10.1097/FJC.0000000000000551. J Cardiovasc Pharmacol. 2018. PMID: 29076887 Free PMC article.
-
[Acute perioperative right heart insufficiency : Diagnostics and treatment].Anaesthesist. 2018 Jan;67(1):61-78. doi: 10.1007/s00101-017-0394-1. Anaesthesist. 2018. PMID: 29270666 German.
-
Preservation of renal function in cardiac surgery patients with low cardiac output syndrome: levosimendan vs beta agonists.BMC Anesthesiol. 2019 Nov 17;19(1):212. doi: 10.1186/s12871-019-0888-2. BMC Anesthesiol. 2019. PMID: 31735161 Free PMC article. Clinical Trial.
-
Case Report: COVID-19 with cytokine storm in a 16-year-old patient: if heart failures comes think about levosimendan.F1000Res. 2023 Feb 7;10:244. doi: 10.12688/f1000research.50782.2. eCollection 2021. F1000Res. 2023. PMID: 38545376 Free PMC article.
References
-
- Orriach Guerrero JL, Ramirez Fernandez A, Iglesias P, et al. Preoperative levosimendan. A new way for organoprotection. Curr Pharm Des. 2014;20(34):5476–5483. - PubMed
-
- Tritapepe L, De Santis V, Vitale D, et al. Levosimendan pretreatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009;102(2):198–204. - PubMed
-
- Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol. 2012;17(3):125–130. - PMC - PubMed
-
- Guerrero-Oriach JL, Navarro-Arce I, Iglesias P, Galán-Ortega M, Rubio-Navarro M, Cruz Mañas J. Preoperative levosimendan for right ventricular dysfunction before heart valve replacement surgery. Rev Esp Cardiol. 2013;66(12):999–1000. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous